(Q36926445)

17 August 2017

1 reference

title

Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations (English)

1 reference

17 August 2017

1 reference

Tyronne I Goonewardene

series ordinal

1

1 reference

17 August 2017

Marcia R Hall

series ordinal

2

1 reference

17 August 2017

Gordon J S Rustin

series ordinal

3

1 reference

17 August 2017

publication date

1 September 2007

1 reference

Lancet Oncology Commission

17 August 2017

published in

1 reference

17 August 2017

volume

8

1 reference

17 August 2017

issue

9

1 reference

17 August 2017

page(s)

813-821

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970273-5

17 August 2017

1 reference

7 January 2021

A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970273-5

7 January 2021

Reactivity of a monoclonal antibody with human ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970273-5

7 January 2021

Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970273-5

7 January 2021

The CA 125 gene: an extracellular superstructure dominated by repeat sequences

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970273-5

7 January 2021

Specificity and Affinity of 26 Monoclonal Antibodies against the CA 125 Antigen: First Report from the ISOBM TD-1 Workshop

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970273-5

7 January 2021

CA 125: the past and the future

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970273-5

7 January 2021

The second generation CA 125 assays.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970273-5

7 January 2021

Tissue Distribution of a Coelomic- Epithelium-Related Antigen Recognized by the Monoclonal Antibody OC125

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970273-5

7 January 2021

Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970273-5

7 January 2021

The effect of the menstrual cycle on serum CA 125 levels: a population study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970273-5

7 January 2021

CA 125 in benign gynecological conditions.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970273-5

7 January 2021

CA 125 (ovarian tumour-associated antigen) in ascitic liver diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970273-5

7 January 2021

Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation☆

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970273-5

7 January 2021

Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970273-5

7 January 2021

Savings obtained by CA-125 measurements during therapy for ovarian carcinoma. The North Thames Ovary Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970273-5

7 January 2021

Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970273-5

7 January 2021

Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970273-5

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970273-5

7 January 2021

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970273-5

7 January 2021

Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970273-5

7 January 2021

Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970273-5

7 January 2021

Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970273-5

7 January 2021

Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970273-5

7 January 2021

Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [seecomments]

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970273-5

7 January 2021

Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970273-5

7 January 2021

The associations between knowledge, CA125 preoccupation, and distress in women with epithelial ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970273-5

7 January 2021

Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970273-5

7 January 2021

2-[Fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970273-5

7 January 2021

Combined PET/CT for detecting recurrent ovarian cancer limited to retroperitoneal lymph nodes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970273-5

7 January 2021

Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970273-5

7 January 2021

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970273-5

7 January 2021

Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970273-5

7 January 2021

Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970273-5

7 January 2021

Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970273-5

7 January 2021

Phase I study of high-dose epirubicin in platinum-pretreated patients with ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970273-5

7 January 2021

Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970273-5

7 January 2021

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970273-5

7 January 2021

Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970273-5

7 January 2021

Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970273-5

7 January 2021

Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970273-5

7 January 2021

Steroid hormone receptors and long term survival in invasive ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970273-5

7 January 2021

Phase II study of high-dose megestrol acetate in platinum-refractory epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970273-5

7 January 2021

Insulin-like growth factor binding proteins IGFBP3, IGFBP4, and IGFBP5 predict endocrine responsiveness in patients with ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970273-5

7 January 2021

Trial of isotretinoin and calcitriol monitored by CA 125 in patients with ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970273-5

7 January 2021

10.1016/S1470-2045(07)70273-5

Identifiers

DOI

1 reference

17 August 2017

1 reference